Kraig Labs Emerges as Last Standing Player in Spider Silk Race

Event summary

  • Kraig Labs has deployed ~1M proprietary spider silk silkworm eggs across 3 production facilities, targeting 10 metric tons/month of recombinant spider silk cocoons.
  • The company's approach uses transgenic silkworms to produce spider silk, a method distinct from fermentation-based competitors.
  • Kraig holds patents covering transgenic silkworm technology, spider silk gene constructs, and resulting fibers.
  • The company has operated without major venture funding, contrasting with competitors that raised over $1B collectively.

The big picture

Kraig Labs represents a rare case of survivorship in the synthetic spider silk category, where better-funded competitors failed to achieve commercial-scale production. The company's biologically aligned approach and patent moat position it uniquely as the field consolidates. Its success could validate transgenic animal biotechnology for structural materials, potentially unlocking new applications in defense, medical, and technical textiles.

What we're watching

Production Validation
Whether Kraig can sustain commercial-scale output at targeted 10-ton monthly threshold.
Market Positioning
How Kraig will differentiate itself as potentially the only viable player in transgenic spider silk production.
Industry Convergence
The pace at which historical sericulture infrastructure integrates with modern genetic engineering.